Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation

Genes Chromosomes and Cancer

Volumn 47, Issue 4, 2008, Pages 267-275

  Håkansson, Petra ^a   Nilsson, Björn ^a   Andersson, Anna ^a   Lassen, Carin ^a   Gullberg, Urban ^b   Fioretos, Thoas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL GROWTH; CELL VIABILITY; CISH GENE; CONTROLLED STUDY; DUSP6 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; METABOLIC REGULATION; NEGATIVE FEEDBACK; PHILADELPHIA 1 CHROMOSOME; PIM1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOCS2 GENE; SOCS3 GENE; TNFAIP3 GENE;

BLOTTING, NORTHERN; BLOTTING, WESTERN; FEEDBACK, BIOCHEMICAL; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 40049090339     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20528     Document Type: Article

References (48)

1. Andersson A, Edén , Lindgren D, Nilsson J, Lassen C, Heldrup J, Fontes M, Borg Å Mitelman F, Johansson B, Höglund M, Fioretos T. 2005. Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia 19:1042-1050.
2. Boros LG, Cascante M, Lee WN. 2002. Metabolic profiling of cell growth and death in cancer: Applications in drug discovery. Drug Discov Today 7:364-372.
3. Bruno E, Horrigan SK, Van Den Berg D, Rozler E, Fitting PR, Moss ST, Westbrook C, Hoffman R. 1998. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood 91:1917-1923.
4. Cacalano NA, Sanden D, Johnston JA. 2001. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol 3:460-465.
5. Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E, Carturan S, Giugliano E, Pautasso M, Bracco E, Rosso V, Sen A, Martinelli G, Baccarani M, Saglio G. 2006. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance, Leukemia 20:61-67.
6. Deininger MW, Goldman JM, Lydon N, Melo JV. 1997. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698.
7. Deininger MW, Goldman JM, Melo JV. 2000. The molecular biology of chronic myeloid leukemia. Blood 96:3343-3356.
8. Deininger M, Buchdunger E, Druker BJ. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653.
9. Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, Rohr UP, Kobbe G, Haeseler A, Gattermann N, Haas R, Kronenwett R. 2007. Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21:494-504.
10. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. 1996. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566.
11. Favre H, Benhamou A, Finidori J, Kelly PA, Edery M. 1999. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett 453:63-66.
12. Fine BM, Stanulla M, Schrappe M, Ho M, Vichmann S, Harbott J, Boxer LM. 2004. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 103:1043-1049.
13. Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB. 1997. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380-394.
14. Håkansson P, Lassen C, Olofsson T, Baldetorp B, Karlsson A, Gullberg U, Fioretos T. 2004a. Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a). Leukemia 18:538-547.
15. Håkansson P, Segal D, Lassen C, Gullberg U, Morse HC, III, Fioretos T, Meltzer PS. 2004b. Identification of genes differentially regulated by the P210 BCR/ABL1 fusion oncogene using cDNA microarrays. Exp Hematol 32:476-482.
16. Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T, Thompson CB. 2004. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res 64:8341-8348.
17. Hosack DA, Dennis G, Jr, Sherman BT, Lane HC, Lempicki RA. 2003. Identifying biological themes within lists of genes with EASE. Genome Biol 4:R70.
18. Hubbard SR. 2002. Protein tyrosine kinases: Autoregulation and small-molecule inhibition. Curr Opin Struct Biol 12:735-741.
19. Ilangumaran S, Ramanathan S, Rottapel R. 2004. Regulation of the immune system by SOCS family adaptor proteins. Semin Immunol 16:351-365.
20. Kanehisa M. 1997. A database for post-genome analysis. Trends Genet 13:375-376.
21. Kanehisa M, Goto S. 2000. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27-30.
22. Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G. 2003. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol 31:504-511.
23. Krebs DL, Hilton DJ. 2001. SOCS proteins: Negative regulators of cytokine signaling. Stem Cells 19:378-387.
24. Lin HK, Bergmann S, Pandolfi PP. 2005. Deregulated TGF-beta signaling in leukemogenesis. Oncogene 24:5693-5700.
25. Liu TC, Lin SF, Chang JG, Yang MY, Hung SY, Chang CS. 2003. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 123:654-661.
26. Melo JV, Deininger MW. 2004. Biology of chronic myelogenous leukemia - Signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 18:545-568.
27. Moller GM, Frost V, Melo JV, Chantry A. 2007. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: Implications for haemopoietic cell growth and chronic myeloid leukaemia. FEBS Lett 581:1329-1334.
28. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. 2002. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236-4243.
29. Naka T, Fujimoto M, Tsutsui H, Yoshimura A. 2005. Negative regulation of cytokine and TLR signalings by SOCS and others. Adv Immunol 87:61-122.
30. Paukku K, Silvennoinen O. 2004. STATs as critical mediators of signal transduction and transcription: Lessons learned from STAT5. Cytokine Growth Factor Rev 15:435-455.
31. Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, Koskinen PJ. 2004. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 103:3744-3750.
32. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. 2006. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103:2794-2799.
33. Randolph TR. 2005. Chronic myelocytic leukemia - Part I: History, clinical presentation, and molecular biology. Clin Lab Sci 18:38-48.
34. Ren R. 2005. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172-183.
35. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS, Jr. 1998. A requirement for NF-kappaB activation in Ber-Abl-mediated transformation. Genes Dev 12:968-981.
36. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. 2002. BioArray Software Environment (BASE): A platform for comprehensive management and analysis of microarray data. Genome Biol 3:SOFTWARE0003.
37. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S. 2002. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100:2926-2931.
38. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942.
39. Schultheis B, Carapeti-Marootian M, Hochhaus A, Weisser A, Goldman JM, Melo JV. 2002. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: Possible inadequacy of a negative feedback mechanism. Blood 99:1766-1775.
40. Takeuchi K, Sakai I, Narumi H, Yasukawa M, Kojima K, Minamoto Y, Fujisaki T, Tanimoto K, Hara M, Numata A, Gondo H, Takahashi M, Fujii N, Masuda K, Fujita S. 2005. Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha. Leuk Res 29:173-178.
41. Tan JC, Rabkin R. 2005. Suppressors of cytokine signaling in health and disease. Pediatr Nephrol 20:567-575.
42. Tauchi T, Yoshimura A, Ohyashiki K. 2001. ClS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway. Exp Hematol 29:356-361.
43. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121.
44. Walz C, Sattler M. 2006. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 57:145-164.
45. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP. 2002. Normalization for cDNA microarray data: A robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30:e15.
46. Yoshimura A. 2005. Negative regulation of cytokine signaling. Clin Rev Allergy Immunol 28:205-220.
47. Zhelev Z, Bakalova R, Ohba H, Ewis A, Ishikawa M, Shinohara Y, Baba Y. 2004. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study). FEBS Lett 570:195-204.
48. Zheng C, Li L, Haak M, Brors B, Frank O, Giehl M, Fabarius A, Schatz M, Weisser A, Lorentz C, Gretz N, Hehlmann R, Hochhaus A, Scifarth W. 2006. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 20:1028-1034.